GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001810512 | Lung | AIS | peptidyl-serine phosphorylation | 60/1849 | 315/18723 | 4.75e-07 | 3.64e-05 | 60 |
GO:001820912 | Lung | AIS | peptidyl-serine modification | 61/1849 | 338/18723 | 2.49e-06 | 1.41e-04 | 61 |
GO:005109813 | Lung | AIS | regulation of binding | 61/1849 | 363/18723 | 2.48e-05 | 8.06e-04 | 61 |
GO:003209212 | Lung | AIS | positive regulation of protein binding | 19/1849 | 85/18723 | 5.23e-04 | 8.42e-03 | 19 |
GO:004339313 | Lung | AIS | regulation of protein binding | 34/1849 | 196/18723 | 8.16e-04 | 1.14e-02 | 34 |
GO:005109913 | Lung | AIS | positive regulation of binding | 30/1849 | 173/18723 | 1.61e-03 | 1.87e-02 | 30 |
GO:003209222 | Lung | AAH | positive regulation of protein binding | 9/613 | 85/18723 | 1.83e-03 | 4.29e-02 | 9 |
GO:001810521 | Lung | MIAC | peptidyl-serine phosphorylation | 37/967 | 315/18723 | 2.73e-06 | 3.12e-04 | 37 |
GO:001820921 | Lung | MIAC | peptidyl-serine modification | 37/967 | 338/18723 | 1.38e-05 | 9.86e-04 | 37 |
GO:00331351 | Lung | MIAC | regulation of peptidyl-serine phosphorylation | 16/967 | 144/18723 | 3.16e-03 | 4.23e-02 | 16 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLCL1 | SNV | Missense_Mutation | | c.1475N>T | p.Gly492Val | p.G492V | Q15111 | protein_coding | tolerated(0.27) | benign(0.021) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLCL1 | SNV | Missense_Mutation | rs780231814 | c.2549N>A | p.Arg850Gln | p.R850Q | Q15111 | protein_coding | deleterious(0.03) | probably_damaging(0.971) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLCL1 | SNV | Missense_Mutation | | c.373C>T | p.Arg125Trp | p.R125W | Q15111 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLCL1 | SNV | Missense_Mutation | novel | c.1050G>T | p.Glu350Asp | p.E350D | Q15111 | protein_coding | tolerated(0.05) | benign(0.118) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLCL1 | SNV | Missense_Mutation | rs201915547 | c.3233N>A | p.Arg1078His | p.R1078H | Q15111 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.862) | TCGA-AX-A1C7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | topotecan | SD |
PLCL1 | SNV | Missense_Mutation | | c.1922N>T | p.Arg641Ile | p.R641I | Q15111 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
PLCL1 | SNV | Missense_Mutation | novel | c.3040N>T | p.Gly1014Cys | p.G1014C | Q15111 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
PLCL1 | SNV | Missense_Mutation | novel | c.527G>T | p.Arg176Ile | p.R176I | Q15111 | protein_coding | deleterious(0.02) | possibly_damaging(0.465) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
PLCL1 | SNV | Missense_Mutation | | c.1081G>A | p.Glu361Lys | p.E361K | Q15111 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
PLCL1 | SNV | Missense_Mutation | novel | c.1194A>C | p.Gln398His | p.Q398H | Q15111 | protein_coding | deleterious(0.03) | possibly_damaging(0.814) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |